Our Content Hub

Key Takeaways from R&D Day 2026: From the Device Renaissance to Enlightenment

Nov 19, 2026, 9:29:59 AM / by Orchestra BioMed posted in Corporate

0 Comments

Key Takeaways from R&D Day 2026: From the Device Renaissance to Enlightenment

Orchestra BioMed Investor Relations Blog | November 2026

Read More

Key Takeaways from HRX Live 2026: Medtronic, Orchestra and KOLs Discuss AVIM Therapy & Expanding the Role of Cardiac Pacing to the Treatment of Hypertensive Heart Disease

Oct 27, 2026, 11:23:21 AM / by Orchestra BioMed posted in Corporate

0 Comments

Key Takeaways from HRX Live 2026: Medtronic, Orchestra and KOLs Discuss AVIM Therapy & Expanding the Role of Cardiac Pacing to the Treatment of Hypertensive Heart Disease

Orchestra BioMed Investor Relations Blog | October 2026

Read More

AVIM Therapy and the Medtronic–Orchestra BioMed Collaboration at HRX Live 2026

Oct 9, 2026, 3:39:05 PM / by Orchestra BioMed posted in Corporate

0 Comments

AVIM Therapy and the Medtronic–Orchestra BioMed Collaboration at HRX Live 2026

Read More

BACKBEAT Pivotal Trial Surpasses Full Enrollment: A Defining Milestone for AVIM Therapy

Oct 8, 2026, 11:59:09 AM / by Orchestra BioMed posted in Clinical

0 Comments

BACKBEAT Pivotal Trial Surpasses Full Enrollment: A Defining Milestone for AVIM Therapy

Orchestra BioMed Investor Relations Blog | October 2026

Read More

LSI Alumni Innovator Spotlight: Orchestra BioMed’s David Hochman, Darren Sherman, and Bill Little

Sep 29, 2026, 9:03:53 AM / by Orchestra BioMed posted in Corporate

0 Comments

LSI Alumni Innovator Spotlight: Orchestra BioMed’s David Hochman, Darren Sherman, and Bill Little

Read More

September Highlights: A Defined Path from Enrollment to Data to Regulatory Submission, Medtronic & Orchestra at HRX, A Milestone Payment, Healthcare Investor Conferences and More

Sep 23, 2026, 12:54:55 PM / by Orchestra BioMed posted in Corporate

0 Comments

September Highlights: A Defined Path from Enrollment to Data to Regulatory Submission, Medtronic & Orchestra at HRX, A Milestone Payment, Healthcare Investor Conferences and More

Orchestra BioMed Investor Relations Blog | September 2026

Read More

David Hochman on the State of Medtech Podcast

Sep 10, 2026, 12:15:00 AM / by Orchestra BioMed posted in Corporate

0 Comments

 

Read More

Q2 2026 Progress Brings Key Pivotal Milestones Into View

Aug 18, 2026, 9:51:16 AM / by Orchestra BioMed posted in Corporate

0 Comments

Q2 2026 Progress Brings Key Pivotal Milestones Into View

Orchestra BioMed Investor Relations Blog | August 2026

Orchestra BioMed recently announced financial results for the second quarter of 2026 and provided a business update across our two pivotal-stage cardiovascular programs. The quarter delivered meaningful clarity on the timeline for primary endpoint results from the BACKBEAT global pivotal trial (“BACKBEAT Trial”) as well as planned regulatory submissions for AVIM Therapy, assuming endpoints are met. We also continued to advance the Virtue SAB in the Treatment of Coronary In-Stent Restenosis Trial (“Virtue Trial”), our investigational device exemption (IDE) randomized pivotal trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis. At the same time, we strengthened our financial foundation to support both programs through their next major milestones. 

Read More

BACKBEAT Timeline Update Reinforces Momentum to Pivotal Trial Data Presentation and Regulatory Submissions by Medtronic

May 27, 2026, 9:00:01 AM / by Orchestra BioMed posted in Finance

0 Comments

BACKBEAT Timeline Update Reinforces Momentum to Pivotal Trial Data Presentation and Regulatory Submissions by Medtronic

Orchestra BioMed Investor Relations Blog | May 2026

Orchestra BioMed recently announced updates to the target timeline for the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”). These important updates provide clarity on the plan for pivotal data presentation as well as Medtronic’s FDA marketing application for Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) for the treatment of uncontrolled hypertension despite anti-hypertensive medications in patients who are also indicated for a pacemaker.

Read More

Strategic Capital Supports Pivotal-Stage Execution

May 8, 2026, 11:08:39 AM / by Orchestra BioMed posted in Finance

0 Comments

Strategic Capital Supports Pivotal-Stage Execution

Orchestra BioMed Investor Relations Blog | May 2026

The receipt of $35 million in strategic capital from Medtronic and Ligand reflects continued partner alignment behind Orchestra BioMed’s pivotal-stage cardiovascular pipeline.

Read More